Miracle Mile Advisors
AXSM icon

Miracle Mile Advisors’s Axsome Therapeutics AXSM Stock Holding History

Miracle Mile Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,010
Closed -$247K – 1049
2026
Q2 		$247K Sell
1,010
-500
-33% -$108K ﹤0.01% 880
2026
Q1 		$255K Buy
+1,510
New +$261K ﹤0.01% 779

Other funds holding AXSM

Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Miracle Mile Advisors's AXSM Position: Q3 2026 in Review

Miracle Mile Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2026, closing a stake of 1,010 shares — an estimated $247K sold.

Miracle Mile Advisors first reported a position in AXSM in Q1 2026 and held it in 2 quarters. The position peaked at $255K in Q1 2026. 286 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Miracle Mile Advisors reported no remaining Axsome Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Miracle Mile Advisors sold 1,010 Axsome Therapeutics shares in Q3 2026, an estimated $247K.
  • Miracle Mile Advisors first reported a position in Axsome Therapeutics in Q1 2026 and held it in 2 quarters.
  • Miracle Mile Advisors's Axsome Therapeutics position peaked at $255K in Q1 2026.
  • 286 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Miracle Mile Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.